MKI67 and meningioma: Prior imaging studies have noted lower ADC values for meningiomas of high cellularity and high Ki-67 indices20, suggesting that meningiomas likely to derive benefit from pembrolizumab were in the less histologically aggressive subset of high-grade meningiomas.